

Supplement Table 1 Definition of some events

Safety Variables	Description
Bleeding events	Any clinically overt sign of hemorrhage that “is actionable” and requires diagnostic studies, hospitalization, or treatment by a health care professional
Combined vascular event	Any event including stroke, myocardial infarction, or Vascular death.
Early neurological deterioration	Within 7 days after stroke attack, an increase in NIHSS of ≥ 2 points or an increase in hemiparesis of ≥ 1 point or an increase in impaired consciousness of ≥ 1 point from baseline and excluding progression of disease due to intracranial hemorrhage by examination of cranial CT or MRI and exacerbation of disease due to other non-stroke causes, such as cardiac insufficiency, hepatic insufficiency, renal insufficiency, etc.
Symptomatic intracranial hemorrhage	According to the Heidelberg bleeding classification: 1) Imaging evidence (brain CT or MRI) of any form of intracranial haemorrhage (Heidelberg class 1a, 1b, 1c, 2, 3a, 3b, 3c, and 3d) 2) Deterioration of clinical symptoms: ≥ 4 points total NIHSS at the time of diagnosis compared to immediately before worsening, or ≥ 2 points in one NIHSS category or leading to intubation, hemicraniectomy, EVD placement or other major surgical intervention.
Vascular death	Deaths caused by any of the following: 1) Stroke diagnosed by imaging, including ischemic stroke and

	<p>hemorrhagic stroke; stroke complications such as stroke-related pneumonia, sepsis, etc.</p> <p>2) Myocardial infarction diagnosed by electrocardiography or hematological indicators.</p> <p>3) Peripheral arterial ischemia with clinical symptoms such as pain or intermittent claudication due to limb ischemia or ankle-brachial index <0.9 or coronary artery bypass grafting or intracoronary stent implantation or amputation, etc.</p> <p>4) Other vasogenic death such as arrhythmia, heart failure, pulmonary embolism, ruptured abdominal aortic aneurysm, hemorrhagic shock, hematocrit acute decreases etc.</p> <p>5) Sudden death or unexplained deaths</p>
--	---

Supplement Table 2 Members of the committee of the trial

Steering Committee
Yilong Wang, Yongjun Wang, S. Claiborne Johnston, Philip M Bath, Xingquan Zhao, Zhongrong Miao, Liping Liu, Zixiao Li
Executive Committee
Yilong Wang, Xiaoling Liao, Ling Guan, Yicong Wang, Baoshan Qiu, Xiaochuan Huo
Data Safety and Monitoring Board
Shuya Li, Hao Li, David Wang
Statistical and Data Management Centre
Yuesong Pan
Clinical Event Adjudication Committee
Hui Qu, Kehui Dong, Yaou Liu